NasdaqGM:CRVSBiotechs
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump?
Corvus Pharmaceuticals (CRVS) has drawn investor interest after recent share price moves, with the stock last closing at $13.05 and a market value of about $1.09b. This highlights heightened attention on this clinical stage biopharma.
See our latest analysis for Corvus Pharmaceuticals.
Recent momentum in Corvus Pharmaceuticals has been strong, with a 7 day share price return of 9.57% and a year to date share price return of 78.28%. The 1 year total shareholder return of 209.98% points to a...